anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The reniform nematode (Rotylenchulus reniformis Linford and Oliveira) adversely impacts the quality and quantity of sweetpotato storage roots. Management of R. reniformis in sweetpotato remains a challenge because host plant resistance is not available, fumigants are detrimental to the environment and health, and crop rotation is not effective. We screened a core set of 24 sweetpotato plant introductions (PIs) against R. reniformis. Four PIs were resistant, and 10 were moderately resistant to R. reniformis, suggesting these PIs can serve as sources of resistance for sweetpotato resistance breeding programs. PI 595869, PI 153907, and PI 599386 suppressed 83 to 89% egg production relative to the susceptible control 'Beauregard', and these PIs were employed in subsequent experiments to determine if their efficacy against R. reniformis can be further increased by applying nonfumigant nematicides oxamyl, fluopyram, and fluensulfone. A 34 to 93% suppression of nematode reproduction was achieved by the application of nonfumigant nematicides, with oxamyl providing the best suppression followed by fluopyram and fluensulfone. Although sweetpotato cultivars resistant to R. reniformis are currently not available and there is a need for the development of safer yet highly effective nonfumigant nematicides, results from the current study suggest that complementing host plant resistance with nonfumigant nematicides can serve as an important tool for effective and sustainable nematode management.
The invention relates to a composition of natural medicines and health food. The composition comprises the following raw materials in parts by weight: 30-140 parts of sauropus spatulifolius beille, 30-140 parts of tea leaves, 10-80 parts of lonicerae flos, and 10-120 parts of lotus leaves. A preparation method of the composition comprises the following steps: adding water to decoct sauropus spatulifolius beille, tea leaves, lonicerae flos and lotus leaves for three times; filtering, merging a filtrate, and concentrating the filtrate till the relative density is 1.05-1.15 (at the temperature of 80 DEG C); preparing paste for later use; adding auxiliary materials to prepare a preparation. The dosage form of the composition is any formulation on the pharmacy, and auxiliary materials in the prior art can be utilized. The preparation is prepared by referring to the method of a conventional traditional Chinese medicine preparation. The composition is capable of clearing heat from throat and improving eyesight, and lowering lipid and relaxing the bowels, is applied to adjuvant therapy on pharyngalgia and cough caused by upper respiratory infection, weight losing and lipid lowering, and is free of toxic and side effects.
Study initiation will commence after the first telephone contact (phone pre-screen), at the baseline visit. Additional lab visits will occur at days 8, 15, and 22 (visits 2-4). At the first study visit, 2/3rds of the participants will be randomly assigned to sample e-cigarettes and 1/3rd will not. Participants in the e-cigarette group will be provided with sufficient product to sample and use as they wish, but with minimal instruction on purpose and level of use (non-use is an outcome). Smokers in the control group will smoke their own brand of cigarettes, as they wish, for the duration of the sampling period. All participants will engage in ecological momentary assessments, which will be completed 3 times daily for 3 weeks. In-person follow-up assessments will be conducted at 1, 2, and 3 months after the final lab visit (Day 22).

Overall, each participant will be contacted 8 times: at the phone pre-screening, the 4 lab visits, and 3 follow-up visits.
In the aging population, choroidal vessels grow through the Bruch's membrane, resulting in a loss of central vision due to choroidal neovascularization (CNV). During active neovascularization, CNV is associated with inappropriate levels of apoptosis in multiple cell types, including choroidal endothelial cells (ChECs). Bim is a pro-apoptotic member of the Bcl-2 family. It is essential for cell apoptosis due to exposure to drugs such as dexamethasone or decreased pro-survival factors, including vascular endothelial growth factor (VEGF). To better elucidate the cell autonomous contribution of Bim expression in the integrity and neovascularization of the choroidal vasculature, we isolated ChECs from wild-type and Bim-deficient (Bim-/-) mice. ChECs lacking Bim expression demonstrated increased expression of VEGF, osteopontin, and the inflammatory cytokines Rantes/Ccl5 and IL6. Bim-/- ChECs were more proliferative and demonstrated an increased capacity to undergo capillary morphogenesis. Anti-VEGF had a diminished capacity to disrupt capillary morphogenesis in Bim-/- ChECs. In vivo, utilizing the mouse laser photocoagulation model, anti-VEGF treatment mitigated CNV in wild-type but not Bim-/- mice. We also tested other modalities that are thought to not require the intrinsic death pathway for their function and showed that propranolol, anti-CTGF, and the TSP1-mimetic peptide ABT898 mitigated CNV in mice lacking Bim expression to varying degrees. Thus, in ChECs, Bim expression could impact the effectiveness of treatment modalities that require the intrinsic death pathway to mitigate CNV.
The invention relates to a drug for treating ulcerative colitis. The drug is prepared from the following raw materials in parts by weight: 8 parts of bighead atractylodes rhizome, 9 parts of round cardamom, 12 parts of rice sprout, 6 parts of sword bean, 6 parts of cirsium japonicum, 6 parts of Chinese angelica, 8 parts of bletilla striata, 6 parts of mile swertia herb, and 9 parts of chingma abutilon seed. Bighead atractylodes rhizome has the functions of invigorating spleen, boosting qi, eliminating dampness, and promoting diuresis. Round cardamom has the functions of resolving dampness, disintegrating lump, moving qi, warming middle jiao, and promoting appetite and digestion. Sword bean has the functions of warming the middle jiao and depressing qi. Cirsium japonicum has the functions of cooling blood and stopping bleeding. Chinese angelica has the functions of tonifying and activating blood. Bletilla striata has the functions of activating blood and promoting tissue regeneration. Mile swertia herb has the functions of clearing liver, draining the gallbladder, clearing heat, and promoting diuresis. Chingma abutilon seed has the functions of clearing heat, and promoting diuresis. The herbals are used together to generate the functions of invigorating the spleen, promoting diuresis, regulating qi, activating blood, removing stasis, and promoting tissue generation. The clinical experiment results show that the provided drug can safely and effectively treat ulcerative colitis.
BACKGROUND AND OBJECTIVE: Non-specific chronic low back pain (NSCLBP) is a prevalent condition causing significant disability and functional impairment. Whole-body vibration exercise (WBVE) has emerged as a new treatment method, but additional research is necessary to determine the optimal parameters of WBVE that would be beneficial for patients experiencing chronic low back pain (CLBP). This study aims to investigate the effects of two type of WBVE (constant vs progressive) on pain, disability, functional performance, and muscle activity in patients with NSCLBP.
METHODS: Thirty-two individuals diagnosed with chronic low back pain (CLBP) without any specific causes were enrolled and randomly assigned to one of two intervention groups: a constant/fixed protocol WBVE group or a progressive protocol WBVE group. Participants underwent WBVE sessions for around 30 min, thrice weekly over a period of 8 weeks. Primary outcomes assessed included pain intensity, functional disability, functional performance, and electromyographic activity of core musculature, measured at baseline and upon completion of the intervention period. Temporal changes of each outcome variable across different periods and between groups were measured with repeated measures 2×2 mixed ANOVA. Further, the paired t-test was performed to compare pre- and post-treatment values within each group.
RESULTS: Significant improvements were observed in both the constant and progressive WBVE protocol groups. Pain intensity decreased by 64.2% (p < 0.001) in the constant group and by 61.1% (p < 0.001) in the progressive group. Functional disability decreased by 48.1% (p < 0.001) in the constant group and by 53.3% (p < 0.001) in the progressive group. Functional performance improved by 16.5% (p < 0.001) in the constant group and by 16.9% (p < 0.001) in the progressive group. Electromyography (EMG) demonstrated significant improvements across all measured variables except % maximum voluntary isometric contraction (%MVIC) of external obliques (EO) in both intervention groups with time (p < 0.001). There was no statistically significant difference in the magnitude of improvement between the constant and progressive WBVE protocols (p > 0.05), indicating both modalities' effectiveness in ameliorating CLBP symptoms and associated functional impairments.
CONCLUSION: The study demonstrates that both progressive and constant WBVE protocols are equally effective in reducing pain and disability in NSCLBP patients. These findings support the inclusion of progressive WBVE in clinical practice, offering a flexible treatment option that can be tailored to individual patient needs, ensuring both tolerability and effectiveness. This contributes valuable evidence towards optimizing WBVE protocols for managing NSCLBP.
INTRODUCTION: Immune checkpoint inhibitors (ICIs) may be associated with hyperprogressive disease (HPD). However, there is currently no standardized definition of HPD, with its risk factors and clinical implications remaining unclear. We investigated HPD in lung cancer patients undergoing immunotherapy, aiming to redefine HPD, identify risk factors, and assess its impact on survival.
METHODS: Clinical and radiologic data from 121 non-small cell lung cancer (NSCLC) patients with 136 immunotherapy cases were reviewed retrospectively. Three HPD definitions (Champiat et al., HPDc; Saâda-Bouzid et al., HPDs; and Ferrara et al., HPDf) were employed. Additionally, all new measurable lesions on the post-treatment CT scan were incorporated in measuring the sum of longest diameters (SLD) to define modified HPD (mHPD).
RESULTS: Among the 121 patients, 4 (3.3%) had HPDc, 11 (9.1%) had HPDs, and none had HPDf. Adding all new measurable lesions increased HPD incidence by 5%-10% across definitions. Multivariate analysis revealed significantly lower progression-free survival (PFS) and overall survival (OS) for patients with HPDc (HR 5.25, P = .001; HR 3.75, P = .015) and HPDs (HR 3.74, P < .001; HR 3.46, P < .001) compared to those without. Patients with mHPD showed similarly poor survival outcomes as HPD patients. Liver metastasis at diagnosis was associated with HPDs, and a high tumor burden correlated with HPDc.
CONCLUSIONS: The incidence and risk factors of HPD varied with different definitions, but mHPD identified more cases with poor outcomes. This comprehensive approach may enhance the identification of at-risk patients and lead to a better understanding of HPD in lung cancer during immunotherapy.
ZYPREXA RELPREVV is available only through a restricted distribution program [see Boxed Warning, Indications and Usage (1), and Patient Counseling Information (17)]. ZYPREXA RELPREVV must not be dispensed directly to a patient. For a patient to receive treatment, the prescriber, healthcare facility, patient, and pharmacy must all be enrolled in the ZYPREXA RELPREVV Patient Care Program. To enroll, call 1-877-772-9390. 

ZYPREXA RELPREVV must be administered in a registered healthcare facility (such as a hospital, clinic, residential treatment center, or community healthcare center) with ready access to emergency response services. After each ZYPREXA RELPREVV injection, a healthcare professional must continuously observe the patient at the healthcare facility for at least 3 hours and must confirm that the patient is alert, oriented, and absent of any signs and symptoms of post-injection delirium/sedation syndrome prior to being released. All patients must be accompanied to their destination upon leaving the facility. For the remainder of the day of each injection, patients should not drive or operate heavy machinery, and should be advised to be vigilant for symptoms of post-injection delirium/sedation syndrome and be able to obtain medical assistance if needed. If post-injection delirium/sedation syndrome is suspected, close medical supervision and monitoring should be instituted in a facility capable of resuscitation [see Overdosage (10)]. If parenteral benzodiazepines are required for patient management during an event of post-injection delirium/sedation syndrome, careful evaluation of clinical status for excessive sedation and cardiorespiratory depression is recommended.
The ventrolateral orbital cortex (VLO) is identified as an integral component of the endogenous analgesic system comprising a spinal cord - thalamic nucleus submedius - VLO - periaqueductal gray (PAG) - spinal cord loop. The present study investigates the effects of 5-HT5A receptor activation in the VLO on allodynia induced by spared nerve injury and formalin-evoked flinching behavior and spinal c-Fos expression in male SD rats, and further examines whether GABAergic modulation is involved in the effects evoked by VLO 5-HT5A receptor activation. We found an upregulation of 5-HT5A receptor expression in the VLO during neuropathic and inflammatory pain states. Microinjection of the non-selective 5-HT5A receptor agonist 5-CT into the VLO dose dependently alleviated allodynia, and flinching behavior and spinal c-Fos expression, which were blocked by the selective 5-HT5A receptor antagonist SB-699551. Moreover, application of the GABAA receptor antagonist bicuculline in the VLO augmented the analgesic effects induced by 5-CT in neuropathic and inflammatory pain states, whereas the GABAA receptor agonist muscimol attenuated these analgesic effects. Additionally, the 5-HT5A receptors were found to be colocalized with GABAergic neurons in the VLO. These results provide new evidence for the involvement of central 5-HT5A receptors in the VLO in modulation of neuropathic and inflammatory pain and support the hypothesis that activation of 5-HT5A receptors may inhibit the inhibitory effect of GABAergic interneurons on output neurons projecting to the PAG (GABAergic disinhibitory mechanisms), consequently activating the brainstem descending inhibitory system that depresses nociceptive transmission at the spinal cord level.
Oral nutrition supplements (ONS) will be given, at maximum, three times per day throughout hospitalization. Upon discharge, participants will be given 4-weeks' worth of oral supplements to take. Adjustments may be made based on indirect calorimetry (IC) measurements.
PROBLEM TO BE SOLVED: To increase the susceptibility of epithelial cells to viral infection and increase the gene transfer efficiency to epithelial tissues when using viruses and viral vectors by increasing transepithelial permeability of the epithelial tissues. SOLUTION: The transepithelial permeability of epithelial tissues, containing epithelial cells (preferably an airway epithelial tissue, e.g. a bronchial tissue, a tracheal tissue or an alveolar tissue) is increased to thereby increase the susceptibility of the epithelial cells to viral infection. Furthermore, the epithelial cells are proliferated by bringing the epithelial cells into contact with a proliferative factor (preferably a growth factor) to thereby achieve an increase in the susceptibility. Furthermore, the increase in the susceptibility can be achieved by bringing the cells of the epithelial tissues into contact with a tissue permealizing agent [preferably a hypotonic solution, an ion chelator (e.g. EGTA), a cationic peptide (e.g. poly-L-lysine), etc.].
An elongate, tubular vibration device 100 with two end caps 106, 110. A motor 115 with eccentric weight 116 is mounted inside the body 102 on a flexible clamp 122, which may be made of plastic or rubber. The motor causes three dimensional cycloidal vibration, so oscillation occurs in each of the three orthogonal planes. The vibration is at frequencies of 15Hz-105Hz and amplitudes of 0.1mm-2mm. The speed of the motor is varied by a control circuit. Optionally, the device may include a tapered handle 120 with a removable applicator 121 to target the vibration. The device may include buttons 144 and a timer for control of the device. A method of using the device to reduce muscle stiffness is also claimed.
The present invention relates to a composition for oral or topical human administration, and its method of preparation. The invention concerns a pentacyclic triterpenoid compound wherein the triterpenoid compound is incorporated into a lipid vesicle surrounded by a tri-layer membrane, preferably a milk fat globule. The triterpenoid compound preferably is betulinic acid, and/or betulin, and/or lupeol, and/or oleanolic acid, and/or ursolic acid, most preferably betulinic acid. The incorporation of the triterpenoid compound into the milk fat globule or lipid vesicle at high payload of at least 10 up to 50 mg/ml is preferably accomplished with high- energy emulsification techniques, most preferably sonication. The composition exists in a preferred embodiment as a liquid emulsion formulation. In another preferred embodiment the composition is a powder that can be prepared by e.g. spray drying or freeze drying techniques from the liquid embodiment of the composition. The composition may preferably be used as pharmaceutical, food supplement or nutraceutical for the treatment or prevention of cancer, type 2 diabetes mellitus, obesity and cardiovascular disease.
Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. For complete responders, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or for 2 courses after complete response criteria are first met. For other patients, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain an active drug component continuously form a medicinal plant containing said active drug component in grown state. CONSTITUTION:The trunk or branch of a medicinal plant (e.g. Phellodendron amurense containing berberine, cinchona containing quinine, magnolia obovata containing magnocurarine, mulverry containing morusin, etc.) is covered 1, and one or more kinds of solutions 3 selected from water, organic solvent, surfactant and oxygen liquid is filled and circulated in the covering 1 to effect the contact of said solution with the bark of said medicinal plant. The active drug component in the bark extracted to the liquid in the covering 1 is adsorbed to an adsorbent 6, which is taken out of the case for the recovery of the active component. EFFECT:In the conventional process, a medicinal plant is grown for a long period for single extraction operation, and the extracted plant is discarded. The waste of resource in the conventional process can be prevented in the present process which enables the continuous extraction and recovery of the active component and facilitates the reutilization of the solvent.
This is a 24-week, randomized, double-blinded, two arm parallel clinical trial comparing metformin ER vs. placebo in combination with a hypocaloric diet (-500 kcal/day). 150 individuals with obesity and increased waist circumference will be randomized to taking metformin ER with hypocaloric diet or placebo with hypocaloric diet. All patients will receive dietary and exercise counseling with the intent of reducing their average caloric intake by 500 kcal/day.
PURPOSE: A cosmetic composition which prevents and treats skin injury due to UV ray using Syngnathoides biaculeatus extract is provided to remarkably remove radical and to suppress oxidative stress and cytotoxicity. CONSTITUTION: A cosmetic composition for preventing and treating skin injury due to UV ray contains 0.01-50 wt% of Syngnathoides biaculeatus extract. The extract is a hot water extract. The hot water extract is prepared by adding Syngnathoides biaculeatus to water, shaking for 3 horus, and filtering with No.2 filter paper. The yield of extract is 15.82%. The antioxidative composition is used in the form of a lotion, cream, and shampoo.
NEW MATERIAL:A cupric salt complex of omega-hydroxyalkyl group-containing macrocyclic polyamine shown by formula I (n is >=4 integer; m and l are 2 or 3). EXAMPLE:A compound shown by formula II. USE:Useful as a super oxide dismutase-like activator. omega-Hydroxyalkyl group introduced as a substituent group to macrocyclic polyamine has no carcinogenicity and is also excellent in terms of solubility in water and other electrolytic solvents. PREPARATION:An alpha-(omega-hydroxyalkyl)malonic acid ester shown by formula III (R is lower alkyl) is condensed with a polyamine shown by formula IV to give a macrocyclic polyamine. Then the macrocyclic polyamine is reacted with a cupric salt such as copper sulfate, etc., in the presence of a solvent such as methanol, etc., to give a compound shown by formula I.
Carcinogenesis: INCRELEX was tumorigenic in rats in a study using doses of 0, 0.25, 1, 4, and 10 mg/kg/day by subcutaneous injection for up to 2 years. The incidence of adrenal medullary hyperplasia and pheochromocytoma increased in male rats given ≥1 mg/kg/day (below clinical exposure at the maximum recommended human dose [MRHD] based on AUC) and in female rats at all dose levels (below clinical exposure at the MRHD based on AUC). The incidence of keratoacanthoma in the skin increased in male rats given 4 and 10 mg/kg/day (approximately the clinical exposure at the MRHD based on AUC). The incidence of mammary gland carcinoma in male rats increased in animals treated with 10 mg/kg/day (3 times the MRHD based on AUC). Only doses that exceeded the maximum tolerated dose (MTD) (based on excess mortality secondary to IGF-1 induced hypoglycemia) caused skin and mammary tumors.

Mutagenesis: INCRELEX was not clastogenic in the in vitro chromosome aberration assay and the in vivo mouse micronucleus assay.

Impairment of fertility: INCRELEX had no effects on fertility in rats using intravenous doses 0.25, 1, and 4 mg/kg/day (up to 3 times the clinical exposure at the MRHD based on BSA).
A 65-year-old man presented with decreased visual acuity in the left eye for 1 month. The diagnosis of hemorrhagic retinal detachment (submacular hemorrhage), which was caused by idiopathic polypoid choroidal vasculopathy, was confirmed by the ultra-wide-angle fundus examination, optical coherence tomography, and B-ultrasound. A vitrectomy combined with an ophthalmic surgical robot-assisted retinal puncture and injection was performed. The recombinant tissue plasminogen activator was injected accurately by the ophthalmic surgical robot between the retinal nerve epithelium and retinal pigment epithelium through a micro-injection needle. During the 2-month follow-up, the subretinal hemorrhage was significantly regressive, the visual acuity of the left eye was improved from hand movement to 0.1, and no other complications were observed. (This article was published ahead of print on the official website of Chinese Journal of Ophthalmology on March 15, 2024).